Fast progression in non–small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel

BACKGROUND: Treatment-induced accelerated tumor growth is a progression pattern reported with immune checkpoint inhibitors that has never been evaluated in randomized phase III studies because it requires two pretreatment scans. This study aimed to develop clinically relevant and applicable criteria...

Descripción completa

Detalles Bibliográficos
Autores principales: Gandara, David, Reck, Martin, Moro-Sibilot, Denis, Mazieres, Julien, Gadgeel, Shirish, Morris, Stefanie, Cardona, Andres, Mendus, Diana, Ballinger, Marcus, Rittmeyer, Achim, Peters, Solange
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7978260/
https://www.ncbi.nlm.nih.gov/pubmed/33737340
http://dx.doi.org/10.1136/jitc-2020-001882

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7978260/
https://www.ncbi.nlm.nih.gov/pubmed/33737340
http://dx.doi.org/10.1136/jitc-2020-001882

Ejemplares similares